Drug Profile

APX 311

Alternative Names: APX-311

Latest Information Update: 17 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 Oct 2023 APX 311 is still in phase I trials in Non-alcoholic steatohepatitis in South Korea (unspecified route) (AptaBio Therapeutics pipeline, October 2023)
16 Oct 2023 AptaBio Therapeutics plans a phase II trial in Non-alcoholic steatohepatitis in 2024 (AptaBio Therapeutics pipeline, October 2023)
16 Oct 2023 AptaBio Therapeutics completes a phase I trial in Non-alcoholic steatohepatitis in South Korea (unspecified route) before October 2023 (AptaBio Therapeutics pipeline, October 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com